Antibodies News and Research

RSS

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.

29 Jan 2009

Early childhood stress has long-term implications

Stressful experiences in early childhood can have long-lasting impacts on kids' health that persist well beyond the resolution of the situation.

27 Jan 2009

Obesity may be contagious!

Professor Nikhil Dhurandhar says a common cold virus can interfere with our normal body processes and make us fat - he has reached this rather astonishing conclusion following ten years of research with both animals and humans into the virus, Adenovirus-36.

27 Jan 2009

Unexpected finding opens up new way to stop autoimmune diseases and transplant rejection

After several years of battling recurring infections, the last thing a patient and her doctors ever expected was that the cause of her problems might actually help millions live longer, more active lives.

23 Jan 2009

Stromedix awarded U.S. patent for antibody-based therapeutics

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that the U.S. Patent Office has granted patent number US 7,465,449, which broadly covers monoclonal antibodies to integrin ávâ6, including compositions related to its lead product, STX-100.

23 Jan 2009

Blocked Interleukin 21 protein prevents Lupus in mouse model

Mice from a strain that ordinarily develops systemic lupus erythematosus (SLE), but bred with a deficiency in receptor for the protein Interleukin 21, stayed healthy and exhibited none of the symptoms of the disease, researchers at The Jackson Laboratory and National Institutes of Health report.

21 Jan 2009

Biotech venture seeks West Nile virus treatment from antibodies in geese

Rich Glynn, a straight-talking entrepreneur from South Dakota, doesn't mince words when explaining why a partnership between his fledgling goose operation and the University of North Dakota is a match made in heaven.

21 Jan 2009

Artificial antibody delivers nanoparticles to tumors

Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.

18 Jan 2009

Microfluidic devices capture and analyze single cancer cells

One of the grand goals in nanotechnology is to develop a single microfluidic device that integrates all of the components needed to perform polymerase chain reaction (PCR)-based nucleic acid analyses. Experts predict that such a device would enable researchers to develop rapid assays for cancer and other life-threatening diseases while a patient is in the doctor's office.

18 Jan 2009

Natural 'defence' gene reveals how oestrogen fuels cancer

CANCER RESEARCH UK scientists have shown for the first time how a natural 'defence' gene involved in fighting infections such as common colds, can be triggered by hormones to ignite and drive cancers like breast, ovarian, and possibly prostate cancer. Their findings are published in the Journal of Experimental Medicine.

13 Jan 2009

Novel low-cost immunotherapy for cancer cells

Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others.

8 Jan 2009

New nasal spray vaccine shown to be effective against botulism

A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .

8 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Antibodies take 'evolutionary leaps' to fight microbes

With cold and flu season in full swing, the fact that viruses and bacteria rapidly evolve is apparent with every sneeze, sniffle, and cough.

5 Jan 2009

PDL BioPharma and Alexion Pharmaceuticals resolve patent dispute

PDL BioPharma, Inc. and Alexion Pharmaceuticals, Inc. today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris (eculizumab) and PDL's patents known as the Queen et al. patents.

5 Jan 2009